GlassScriptPhysician profile
Macey Dodd
NPI 1275199820
$533.32
in general payments reported to CMS, 2019-2025
13 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $32.42 · 2024: $124 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $449 · Long Term Medical Supply Or Device Loan: $49.95 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $449.37 |
| Long Term Medical Supply Or Device Loan | $49.95 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $130.91 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.36 | 2025 | Caplyta |
| Abbott Laboratories | $49.95 | 2024 | Freestyle Insulinx |
| Phathom Pharmaceuticals, INC. | $49.01 | 2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $45.50 | 2024-2025 | Airsupra, Farxiga |
| Becton, Dickinson and Company | $34.00 | 2025 | Introducer Needle |
| Paratek Pharmaceuticals, INC. | $31.04 | 2025 | Xhance, Nuzyra |
| Axsome Therapeutics, INC. | $29.59 | 2025 | Auvelity |
| Pfizer INC. | $26.39 | 2024 | |
| Verona Pharma, INC. | $25.42 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $19.88 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.02 | 2023 | Xifaxan |
| Lilly USA, LLC | $13.25 | 2024 | Zepbound, Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Macey Dodd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.